In murine models of cancer, we have achieved efficient systemic activation of tumor-specific T cells by the local administration of a CTLA4-blocking antibody at low doses. Using a slow-release formulation, we could drastically lower the serum levels of the antibody, hence decreasing adverse effects and the risk of autoimmune reactions, without losing systemic efficacy. © 2013 Landes Bioscience.
Fransen, M. F., Ossendorp, F., Arens, R., & Melief, C. J. M. (2013). Local immunomodulation for cancer therapy: Providing treatment where needed. OncoImmunology, 2(11), [e26493]. https://doi.org/10.4161/onci.26493